ALNY - Alnylam Pharmaceuticals Inc. (ALNY) Q4 2023 Earnings Call Transcript
2024-02-15 13:16:06 ET
Alnylam Pharmaceuticals, Inc. (ALNY)
Q4 2023 Earnings Conference Call
February 15, 2024 08:30 ET
Company Participants
Christine Lindenboom - Senior Vice President, Investor Relations and Corporate Communications
Yvonne Greenstreet - Chief Executive Officer
Tolga Tanguler - Chief Commercial Officer
Pushkal Garg - Chief Medical Officer
Jeff Poulton - Chief Financial Officer
Akshay Vaishnaw - Chief Innovation Officer
Conference Call Participants
Ritu Baral - TD
Paul Matteis - Stifel
Ellie Merle - UBS
Kostas Biliouris - BMO Capital Markets
David Lebowitz - Citi
Jessica Fye - JPMorgan
Luca Issi - RBC Capital
Salveen Richter - Goldman Sachs
Gena Wang - Barclays
Maury Raycroft - Jefferies
Mike Ulz - Morgan Stanley
William Pickering - Bernstein
Presentation
Operator
Good day and thank you for standing by. Welcome to the Alnylam Pharmaceuticals Q4 2023 Earnings Conference Call. [Operator Instructions] After the speaker’s presentation, there will be a question-and-answer session. Please be advised that today’s conference is being recorded. I would now like to hand the conference call over to the company.
Christine Lindenboom
Good morning. I am Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at Alnylam. With me today are Yvonne Greenstreet, Chief Executive Officer; Tolga Tanguler, Chief Commercial Officer; Pushkal Garg, Chief Medical Officer; and Jeff Poulton, Chief Financial Officer. Also on the line and available for Q&A is Akshay Vaishnaw, Chief Innovation Officer.
For those of you participating via conference call, the accompanying slides can be accessed by going to the Events section of the Investors page of our website, investors.alnylam.com/events.
During today’s call, as outlined on Slide 2, Yvonne will offer some introductory remarks and provide general context; Tolga will provide an update on our global commercial progress; Pushkal will review pipeline updates and clinical progress; and Jeff will review our financials and guidance, followed by a summary of upcoming milestones before we open the call for your questions.
I would like to remind you that this call will contain remarks concerning Alnylam’s future expectations, plans and prospects, which constitute forward-looking statements for the purposes of the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recent periodic report on file with the SEC....
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2023 Earnings Call Transcript